Qiagen (NYSE:QGEN) Releases FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.280- for the period, compared to the consensus estimate of 2.350. The company issued revenue guidance of $2.1 billion-, compared to the consensus revenue estimate of $2.1 billion. Qiagen also updated its Q1 2025 guidance to 0.500- EPS.

Qiagen Price Performance

NYSE:QGEN traded down $1.41 during midday trading on Friday, hitting $41.03. 531,564 shares of the stock were exchanged, compared to its average volume of 1,204,042. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $9.10 billion, a price-to-earnings ratio of 102.16, a P/E/G ratio of 3.10 and a beta of 0.36. Qiagen has a one year low of $40.15 and a one year high of $49.30. The business has a 50-day moving average price of $43.80 and a two-hundred day moving average price of $43.25.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. Sell-side analysts predict that Qiagen will post 2.23 EPS for the current year.

Analysts Set New Price Targets

QGEN has been the subject of several research reports. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price for the company. in a research note on Thursday, October 17th. Jefferies Financial Group restated a “buy” rating and issued a $52.50 price target (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. UBS Group reduced their target price on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday. Morgan Stanley reiterated an “equal weight” rating and issued a $46.67 target price (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.84.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.